Jin-hua Huang

State Key Laboratory Of Oncology In South China
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Fine-tuned lightweight language models for structured extraction of liver cancer imaging free-text report: a comparative analysis with existing large language models.

Fine-tuned lightweight language models for structured extraction of liver cancer imaging free-text report: a comparative analysis with existing large language models.

Journal: BMC medical imaging

Published: December 27, 2025

Long-term outcomes of ablation versus surgery in patients with colorectal carcinoma pulmonary oligometastases: a single-center, retrospective cohort study.

Long-term outcomes of ablation versus surgery in patients with colorectal carcinoma pulmonary oligometastases: a single-center, retrospective cohort study.

Journal: International journal of surgery (London, England)

Published: May 09, 2025

Long-Term Outcomes of Transarterial Chemoembolization plus Ablation versus Surgical Resection in Patients with Large BCLC Stage A/B HCC.

Long-Term Outcomes of Transarterial Chemoembolization plus Ablation versus Surgical Resection in Patients with Large BCLC Stage A/B HCC.

Journal: Academic radiology

Published: December 27, 2024

Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status.

Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status.

Journal: Breast (Edinburgh, Scotland)

Published: October 29, 2024

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Journal: EClinicalMedicine

Published: January 10, 2024

A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial.

A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial.

Journal: Liver cancer

Published: August 17, 2023

Myocardial and Cerebral Infarction after Transarterial Bland Microsphere Embolization for Hepatocellular Carcinoma: A Case Report.

Myocardial and Cerebral Infarction after Transarterial Bland Microsphere Embolization for Hepatocellular Carcinoma: A Case Report.

Journal: Journal of vascular and interventional radiology : JVIR

Published: July 22, 2023

Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study.

Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study.

Journal: Signal transduction and targeted therapy

Published: July 04, 2023

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).

Journal: Signal transduction and targeted therapy

Published: June 14, 2022

Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy.

Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy.

Journal: BMC gastroenterology

Published: October 28, 2021

CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.

CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.

Journal: Bioscience reports

Published: May 10, 2021

Adjuvant cytokine-induced killer cells with minimally invasive therapies augmented therapeutic efficacy of unresectable hepatocellular carcinoma.

Adjuvant cytokine-induced killer cells with minimally invasive therapies augmented therapeutic efficacy of unresectable hepatocellular carcinoma.

Journal: Journal of cancer research and therapeutics

Published: February 10, 2021

Showing 1-12 of 43

Last Updated: 09/26/2026